Apogee Therapeutics | 4:持股变动声明-董事 McKenna Mark C.
Apogee Therapeutics | 4:持股变动声明-高管 Dambkowski Carl
Apogee Therapeutics | 4:持股变动声明-高管 HENDERSON MICHAEL THOMAS
Apogee Therapeutics | 4:持股变动声明-高管 Henderson Jane
Apogee Therapeutics | 4:持股变动声明-高管 Dambkowski Carl
Apogee Therapeutics | 144:拟议出售证券
Apogee Therapeutics | 8-K:重大事件
Apogee Therapeutics | 4:持股变动声明-高管 Dambkowski Carl
Apogee Therapeutics | 4:持股变动声明-高管 HENDERSON MICHAEL THOMAS
Apogee Therapeutics | 144:拟议出售证券
Apogee Therapeutics | 8-K:重大事件
Apogee Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-RA Capital Management, L.P.(3.4%),Peter Kolchinsky(3.4%)等
Apogee Therapeutics | SC 13G:超过5%持股股东披露文件-DRIEHAUS CAPITAL MANAGEMENT LLC(5.63%)
Apogee Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Deep Track Capital, LP(2.22%),Deep Track Biotechnology Master Fund, Ltd.(2.22%)等
Apogee Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-FMR LLC(16.672%),Abigail P. Johnson(16.672%)
Apogee Therapeutics | 8-K:Apogee Therapeutics提供管道进展并公布2024年第三季度财务业绩
Apogee Therapeutics | 10-Q:2024财年三季报
Apogee Therapeutics | 4:持股变动声明-高管 Dambkowski Carl
Apogee Therapeutics | 4:持股变动声明-高管 HENDERSON MICHAEL THOMAS
Apogee Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(6.6%)
暂无数据